ทิศทางการรักษาโรค oral melanoma (OM) ในสุนัขโดยใช้ภูมิคุ้มกันบำบัด
Article Sidebar
เผยแพร่แล้ว:
ต.ค. 26, 2018
คำสำคัญ:
มะเร็งเมลาโนมาในช่องปาก ภูมิคุ้มกันรักษามะเร็ง ดีเอ็นเอวัคซีน chimerised anti-PD-L1 โมโนโคลนอลแอนติบอดี
Main Article Content
บทคัดย่อ
โรคมะเร็งเมลาโนมาในช่องปาก (oral melanoma; OM) ในสุนัขเกิดจากการเพิ่มจำนวนที่มากผิดปกติของเซลล์เมลาโนไซต์ ซึ่งเป็นเซลล์ที่สร้างเม็ดสีเมลานิน โดยมะเร็งชนิดนี้เกิดได้ในบริเวณผิวหนังทั่วไป รวมทั้งบริเวณตา เยื่อเมือก และช่องปากของสุนัข ซึ่งมะเร็งมักมีการแพร่กระจายไปยังบริเวณอวัยวะข้างเคียงโดยเฉพาะกระดูกกราม มีรายงานว่าพบได้มากในสุนัขช่วงอายุ 8-11 ปี และมีสีขนสีดำหรือมีผิวหนังสีดำ มีการรักษาโรค OM ด้วยวิธีการผ่าตัด การใช้รังสีรักษา การใช้สารเคมี รวมทั้งมีการรักษาร่วมกันหลายวิธี แต่พบว่ามะเร็งระยะ 3 และ 4 มักไม่การตอบสนองต่อการรักษารูปแบบเก่า ปัจจุบันเมื่อความรู้ระดับโมเลกุลมากขึ้น มีการคิดค้นการรักษา OM ที่ทันสมัยขึ้นและเน้นการรักษาแบบมุ่งเป้าโดยการใช้ภูมิคุ้มกันบำบัด การรักษาที่ทันสมัยในปัจจุบันมีการใช้ไทโรซิเนสดีเอ็นเอวัคซีน (huTyr) ซึ่งมีลักษณะคล้ายกับแอนติเจนของเซลล์มะเร็งฉีดให้กับสุนัขเพื่อกระตุ้นให้สุนัขสร้างภูมิคุ้มกันที่สามารถออกฤทธิ์ทำลายเซลล์มะเร็งได้เอง รวมทั้งมีการพัฒนาแอนติบอดีที่สามารถเข้าขัดขวางการจับกันระหว่าง checkpoint protein ชนิด programmed death 1 (PD-1) ของเซลล์ภูมิคุ้มกัน กับ PD-ligand 1 (PD-L1) ในเซลล์มะเร็ง ซึ่งการเข้าขัดขวางการจับกันระหว่าง PD-1 และ PD-L1 นี้จะสามารถกระตุ้นการทำงานของ T cell และทำให้ T cell สามารถหลั่ง cytokine หรือ chemokine ออกมาทำลายมะเร็ง การรักษา OM ด้วยการใช้แอนติบอดีที่เฉพาะเจาะจงนี้เป็นวิธีการรักษา OM ด้วยภูมิคุ้มกัน ซึ่งกำลังเป็นที่สนใจและมีการพิสูจน์ว่าสามารถใช้กับรายที่เป็น OM ในระยะท้ายที่มีการแพร่กระจายมะเร็งไปยังปอดได้ เหมาะแก่การศึกษาเพื่อพัฒนาให้สามารถนำมาใช้ได้อย่างแพร่หลายมากขึ้น
Article Details
ประเภทบทความ
บทความปริทัศน์
เอกสารอ้างอิง
Bergman, P.J., McKnight, J., Novosad, A., Charney, S., Farrelly, J., Craft, D., Wulderk, M., Jeffers, Y., Sadelain, M., Hohenhaus, A.E., Segal, N., Gregor, P., Engelhorn, M., Riviere, I., Houghton, A.N. and Wolchok J.D. 2003. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical Cancer Research 9(4), 1284-1290.
Bergman, P.J. 2007. Canine oral melanoma. Clinical Techniques in Small Animal Practice 22(2), 55-60.
Blanchard, T., Srivastava, P.K. and Duan F. 2013.Vaccines against advanced melanoma. Clinics in Dermatology 31(2), 179-190.
Boria, P.A., Murry, D.J., Bennett, P.F., Glickman, N.W., Snyder, P.W., Merkel, B.L., Schlittler, D.L., Mutsaers, A.J., Thomas, R.M. and Knapp, D.W. 2004. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association 224(3), 388-394.
Brockley, L.K., Cooper, M.A., Bennett, P.F. 2013. Malignant melanoma in 63 dogs (2001–2011): the effect of carboplatin chemotherapy on survival. New Zealand Veterinary Journal 61(1), 25-31.
Dobson, J.M. 2013. Breed-predispositions to cancer in pedigree dogs. ISRN Veterinary Science 1-23.
Finocchiaro, L.M., Fondello, C., Gil-Cardeza M.L., Rossi U.A., Villaverde M.S., Riveros M.D. and Glikin G.C. 2015. Cytokine-enhanced vaccine and interferon-β plus suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Human Gene Therapy 26(6), 367-376.
Freeman, K.P., Hahn, K.A., Harris, F.D. and King, G.K. 2003. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987–1997). Journal of Veterinary Internal Medicine 17(1), 96-101.
Gillard, M., Cadieu, E., De Brito, C., Abadie, J., Vergier, B., Devauchelle, P., Degorce, F., Dréano, S., Primot, A., Dorso, L., Lagadic, M., Galibert, F., Hédan, B., Galibert, M.-D. and André, C. 2014. Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas. Pigment Cell & Melanoma Research 27(1), 90-102.
Hartley, G., Faulhaber, E., Caldwell, A., Coy, J., Kurihara, J., Guth, A., Regan, D. and Dow, S. 2017. Immune regulation of canine tumour and macrophage PD-L1 expression. Veterinary and Comparative Oncology 15(2), 534-549.
Kawabe, M., Mori, T., Ito, Y., Murakami, M., Sakai, H., Yanai, T. and Maruo K. 2015. Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006-2012). Journal of the American Veterinary Medical Association 247(10), 1146-1153.
Lee, C., Collichio, F., Ollila, D. and Moschos, S. 2013. Historical review of melanoma treatment and outcomes. Clinics in Dermatology 31(2), 141-147.
Liao, J.C.F., Gregor P., Wolchok J.D., Orlandi F., Craft D., Leung C., Houghton A.N. and Bergman P.J. 2006. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immunity 6(1), 8.
MacEwen, E.G.; Patnaik, A.K.; Harvey, H.J.; Hayes, A.A.; Matus, R. 1986. Canine oral melanoma: Comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Investigation 4, 397-402.
Maekawa, N., Konnai, S., Ikebuchi, R., Okagawa, T., Adachi, M., Takagi, S., Kagawa, Y., Nakajima, C., Suzuki, Y., Murata, S. and Ohashi, K. 2014. Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade. PLoS One 9(6), e98415.
Maekawa, N., Konnai, S., Okagawa, T., Nishimori, A., Ikebuchi, R., Izumi, Y., Takagi, S., Kagawa, Y., Nakajima, C., Suzuki, Y., Kato, Y., Murata, S. and Ohashi, K. 2016. Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma. PLoS One 11(6), e0157176.
Maekawa, N., Konnai, S., Takagi, S., Kagawa, Y., Okagawa, T., Nishimori, A., Ikebuchi, R., Izumi, Y., Deguchi, T., Nakajima, C., Kato, Y., Yamamoto, K., Uemura, H., Suzuki, Y., Murata, S. and Ohashi, K. 2017. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Scientific Reports 7(1), 8951.
Manley, C.A., Leibman, N.F., Wolchok, J.D., Riviere, I.C., Bartido, S., Craft, D.M. and Bergman, P.J. 2011. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of veterinary internal medicine 25(1), 94-99.
McLean, J.L. and Lobetti R.G. 2015. Use of the melanoma vaccine in 38 dogs: The South African experience. Journal of the South African Veterinary Association 86(1), 1-4.
Modiano, J.F., Ritt, M.G. and Wojcieszyn, J. 1999. The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. Journal of Veterinary Internal Medicine 13(3), 163-174.
Nishiya, A.T., Massoco, C.O., Felizzola, C.R., Perlmann, E., Batschinski, K., Tedardi, M.V., Garcia, J.S., Mendonça, P.P., Teixeira, T.F. and Zaidan Dagli, M.L. 2016. Comparative aspects of canine melanoma. Veterinary Sciences 3(1), 7.
Ottnod, J.M., Smedley R.C., Walshaw R., Hauptman J.G., Kiupel M. and Obradovich, J.E.. 2013. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Veterinary and Comparative Oncology 11(3), 219-229.
Riccardo, F., Iussich, S., Maniscalco, L., Mayayo, S.L, La Rosa, G., Arigoni, M., De Maria, R., Gattino, F., Lanzardo, S., Lardone, E., Martano, M., Morello, E., Prestigio, S., Fiore, A., Quaglino, E., Zabarino, S., Ferrone, S., Buracco, P. and Cavallo, F. 2014. CSPG4-Specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clinical Cancer Research 20(14), 3753-3762.
Teixeira, T.F., Silva, T.C.D., Cogliati, B., Nagamine, M.K., and Dagli, M.L.Z. 2010. Retrospective study of melanocytic neoplasms in dogs and cats. Brazilian Journal of Veterinary Pathology 3, 100-104.
Teixeira, T.F., Gentile, L.B., Da Silva, T.C., Mennecier, G., Chaible, L.M., Cogliati, B., Roman, M.A., Gioso, M.A. and Dagli, M.L. 2014. Cell proliferation and expression of connexins differ in melanotic and amelanotic canine oral melanomas. Veterinary Research Communications 38(1), 29-38.
Topalian, S.L., Hodi F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M. and Sznol, M. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 366(26), 2443-2454.
Treggiari, E., Grant, J.P. and North S.M. 2016. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma. The Journal of Veterinary Medical Science 78(5), 845-850.
Verganti, S., Berlato, D., Blackwood, L., Amores-Fuster, I., Polton, G.A., Elders, R., Doyle, R., Taylor, A. and Murphy S. 2017. Use of Oncept melanoma vaccine in 69canine oral malignant melanomas in the UK. Journal of Small Animal Practice 58(1), 10-16.
Wong, R.M., Scotland, R.R., Lau, R.L., Wang, C., Korman, A.J., Kast, W.M. and Weber, J.S. 2007. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. International Immunology 19(10), 1223-1234.
Zitvogel, L. and Kroemer, G. 2012. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1, 1223-1225.
Bergman, P.J. 2007. Canine oral melanoma. Clinical Techniques in Small Animal Practice 22(2), 55-60.
Blanchard, T., Srivastava, P.K. and Duan F. 2013.Vaccines against advanced melanoma. Clinics in Dermatology 31(2), 179-190.
Boria, P.A., Murry, D.J., Bennett, P.F., Glickman, N.W., Snyder, P.W., Merkel, B.L., Schlittler, D.L., Mutsaers, A.J., Thomas, R.M. and Knapp, D.W. 2004. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association 224(3), 388-394.
Brockley, L.K., Cooper, M.A., Bennett, P.F. 2013. Malignant melanoma in 63 dogs (2001–2011): the effect of carboplatin chemotherapy on survival. New Zealand Veterinary Journal 61(1), 25-31.
Dobson, J.M. 2013. Breed-predispositions to cancer in pedigree dogs. ISRN Veterinary Science 1-23.
Finocchiaro, L.M., Fondello, C., Gil-Cardeza M.L., Rossi U.A., Villaverde M.S., Riveros M.D. and Glikin G.C. 2015. Cytokine-enhanced vaccine and interferon-β plus suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Human Gene Therapy 26(6), 367-376.
Freeman, K.P., Hahn, K.A., Harris, F.D. and King, G.K. 2003. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987–1997). Journal of Veterinary Internal Medicine 17(1), 96-101.
Gillard, M., Cadieu, E., De Brito, C., Abadie, J., Vergier, B., Devauchelle, P., Degorce, F., Dréano, S., Primot, A., Dorso, L., Lagadic, M., Galibert, F., Hédan, B., Galibert, M.-D. and André, C. 2014. Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas. Pigment Cell & Melanoma Research 27(1), 90-102.
Hartley, G., Faulhaber, E., Caldwell, A., Coy, J., Kurihara, J., Guth, A., Regan, D. and Dow, S. 2017. Immune regulation of canine tumour and macrophage PD-L1 expression. Veterinary and Comparative Oncology 15(2), 534-549.
Kawabe, M., Mori, T., Ito, Y., Murakami, M., Sakai, H., Yanai, T. and Maruo K. 2015. Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006-2012). Journal of the American Veterinary Medical Association 247(10), 1146-1153.
Lee, C., Collichio, F., Ollila, D. and Moschos, S. 2013. Historical review of melanoma treatment and outcomes. Clinics in Dermatology 31(2), 141-147.
Liao, J.C.F., Gregor P., Wolchok J.D., Orlandi F., Craft D., Leung C., Houghton A.N. and Bergman P.J. 2006. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immunity 6(1), 8.
MacEwen, E.G.; Patnaik, A.K.; Harvey, H.J.; Hayes, A.A.; Matus, R. 1986. Canine oral melanoma: Comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Investigation 4, 397-402.
Maekawa, N., Konnai, S., Ikebuchi, R., Okagawa, T., Adachi, M., Takagi, S., Kagawa, Y., Nakajima, C., Suzuki, Y., Murata, S. and Ohashi, K. 2014. Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade. PLoS One 9(6), e98415.
Maekawa, N., Konnai, S., Okagawa, T., Nishimori, A., Ikebuchi, R., Izumi, Y., Takagi, S., Kagawa, Y., Nakajima, C., Suzuki, Y., Kato, Y., Murata, S. and Ohashi, K. 2016. Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma. PLoS One 11(6), e0157176.
Maekawa, N., Konnai, S., Takagi, S., Kagawa, Y., Okagawa, T., Nishimori, A., Ikebuchi, R., Izumi, Y., Deguchi, T., Nakajima, C., Kato, Y., Yamamoto, K., Uemura, H., Suzuki, Y., Murata, S. and Ohashi, K. 2017. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Scientific Reports 7(1), 8951.
Manley, C.A., Leibman, N.F., Wolchok, J.D., Riviere, I.C., Bartido, S., Craft, D.M. and Bergman, P.J. 2011. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of veterinary internal medicine 25(1), 94-99.
McLean, J.L. and Lobetti R.G. 2015. Use of the melanoma vaccine in 38 dogs: The South African experience. Journal of the South African Veterinary Association 86(1), 1-4.
Modiano, J.F., Ritt, M.G. and Wojcieszyn, J. 1999. The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. Journal of Veterinary Internal Medicine 13(3), 163-174.
Nishiya, A.T., Massoco, C.O., Felizzola, C.R., Perlmann, E., Batschinski, K., Tedardi, M.V., Garcia, J.S., Mendonça, P.P., Teixeira, T.F. and Zaidan Dagli, M.L. 2016. Comparative aspects of canine melanoma. Veterinary Sciences 3(1), 7.
Ottnod, J.M., Smedley R.C., Walshaw R., Hauptman J.G., Kiupel M. and Obradovich, J.E.. 2013. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Veterinary and Comparative Oncology 11(3), 219-229.
Riccardo, F., Iussich, S., Maniscalco, L., Mayayo, S.L, La Rosa, G., Arigoni, M., De Maria, R., Gattino, F., Lanzardo, S., Lardone, E., Martano, M., Morello, E., Prestigio, S., Fiore, A., Quaglino, E., Zabarino, S., Ferrone, S., Buracco, P. and Cavallo, F. 2014. CSPG4-Specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clinical Cancer Research 20(14), 3753-3762.
Teixeira, T.F., Silva, T.C.D., Cogliati, B., Nagamine, M.K., and Dagli, M.L.Z. 2010. Retrospective study of melanocytic neoplasms in dogs and cats. Brazilian Journal of Veterinary Pathology 3, 100-104.
Teixeira, T.F., Gentile, L.B., Da Silva, T.C., Mennecier, G., Chaible, L.M., Cogliati, B., Roman, M.A., Gioso, M.A. and Dagli, M.L. 2014. Cell proliferation and expression of connexins differ in melanotic and amelanotic canine oral melanomas. Veterinary Research Communications 38(1), 29-38.
Topalian, S.L., Hodi F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M. and Sznol, M. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 366(26), 2443-2454.
Treggiari, E., Grant, J.P. and North S.M. 2016. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma. The Journal of Veterinary Medical Science 78(5), 845-850.
Verganti, S., Berlato, D., Blackwood, L., Amores-Fuster, I., Polton, G.A., Elders, R., Doyle, R., Taylor, A. and Murphy S. 2017. Use of Oncept melanoma vaccine in 69canine oral malignant melanomas in the UK. Journal of Small Animal Practice 58(1), 10-16.
Wong, R.M., Scotland, R.R., Lau, R.L., Wang, C., Korman, A.J., Kast, W.M. and Weber, J.S. 2007. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. International Immunology 19(10), 1223-1234.
Zitvogel, L. and Kroemer, G. 2012. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1, 1223-1225.
